Coloplast Overview
- Year Founded
-
1954
- Status
-
Public
- Employees
-
17,775
- Stock Symbol
-
COLO B
- Investments
-
15
- Share Price
-
$73.86
- (As of Wednesday Closing)
Coloplast General Information
Description
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
Contact Information
Website
www.coloplast.comCorporate Office
- Holtedam 1-3
- 3050 Humlebaek
- Denmark
Corporate Office
- Holtedam 1-3
- 3050 Humlebaek
- Denmark
Coloplast Stock Performance
As of 18-Nov-2026, Coloplast’s stock price is $73.86. Its current market cap is $16.6B with 225M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $73.86 | $74.73 | $56.30 - $91.70 | $16.6B | 225M | 378K | $2.12 |
Coloplast Financials Summary
As of 30-Sep-2026, Coloplast has a trailing 12-month revenue of $4.5B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Sep-2026 | FY 2025 30-Sep-2025 | FY 2024 30-Sep-2024 |
|---|---|---|---|---|
| EV | 17,774,280 | 17,774,280 | 22,923,071 | 33,033,977 |
| Revenue | 4,499,827 | 4,499,827 | 4,121,050 | 3,929,110 |
| EBITDA | 1,386,129 | 1,386,129 | 1,232,441 | 1,221,033 |
| Net Income | 477,954 | 477,954 | 537,567 | 734,364 |
| Total Assets | 7,019,005 | 7,019,005 | 7,601,098 | 7,200,470 |
| Total Debt | 3,264,280 | 3,264,280 | 3,557,823 | 3,389,417 |
Coloplast Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Coloplast Comparisons
Industry
Financing
Details
Coloplast Competitors (22)
One of Coloplast’s 22 competitors is Smith & Nephew, a Corporation company based in Watford, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Smith & Nephew | Corporation | Watford, United Kingdom | ||||
| Avanos Medical | Private Equity-Backed | Alpharetta, GA | ||||
| Aspen Surgical Products | Private Equity-Backed | Caledonia, MI | ||||
| Kimal | Formerly Accelerator/Incubator backed | Worcester, United Kingdom | ||||
| Medtronic | Corporation | Minneapolis, MN |
Coloplast Patents
Coloplast Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-D1152011-S1 | Adhesive nose patch | Active | 22-May-2025 | ||
| WO-2026228884-A1 | An ostomy appliance liner assembly and a method of removing | Pending | 02-May-2025 | ||
| WO-2026223871-A1 | A heat and moisture exchanging (hme) device | Pending | 23-Apr-2025 | ||
| WO-2026184827-A1 | A sleeve, an anal irrigation device and a kit of parts | Pending | 07-Mar-2025 | ||
| WO-2026162112-A1 | A urinary catheter and a connector with pressure equalization | Pending | 29-Jan-2025 | A61M25/0017 |
Coloplast Signals
Coloplast Investments & Acquisitions (15)
Coloplast’s most recent deal was a Merger/Acquisition with Uromedica for . The deal was made on 18-Feb-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Uromedica | 18-Feb-2026 | Merger/Acquisition | Therapeutic Devices | ||
| Francis Medical | 16-Dec-2024 | Later Stage VC | Surgical Devices | ||
| Kerecis | 31-Aug-2023 | Merger/Acquisition | Drug Discovery | ||
| Atos Medical | 08-Nov-2021 | Merger/Acquisition | Therapeutic Devices | ||
| Francis Medical | 15-Sep-2021 | Early Stage VC | Surgical Devices |
Coloplast ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
17.71 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Supplies
Subindustry
of 60
Rank
Percentile
Coloplast Exits (2)
Coloplast’s most recent exit was on 01-Jun-2006 from Mills Biopharmaceuticals. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Mills Biopharmaceuticals | 01-Jun-2006 | Completed |
|
||
| Amoena | 01-Jan-1996 | Merger/Acquisition | Completed |
Coloplast Affiliates
Subsidiaries (18)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Coloplast Finance | Dk Humlebæk, Netherlands | 2022 | |
| Atos Medical Holding | Malmo, Sweden | 2016 | |
| ATOS MEDICAL France | Bagneux, France | 2010 | |
| Comfort Medical | Coral Springs, FL | 2010 | |
| Coloplast Business Centre | Szczecin, Poland | 2009 |
Coloplast FAQs
-
When was Coloplast founded?
Coloplast was founded in 1954.
-
Where is Coloplast headquartered?
Coloplast is headquartered in Humlebaek, Denmark.
-
What is the size of Coloplast?
Coloplast has 17,775 total employees.
-
What industry is Coloplast in?
Coloplast’s primary industry is Medical Supplies.
-
Is Coloplast a private or public company?
Coloplast is a Public company.
-
What is Coloplast’s stock symbol?
The ticker symbol for Coloplast is COLO B.
-
What is the current stock price of Coloplast?
As of 18-Nov-2026 the stock price of Coloplast is $73.86.
-
What is the current market cap of Coloplast?
The current market capitalization of Coloplast is $16.6B.
-
What is Coloplast’s current revenue?
The trailing twelve month revenue for Coloplast is $4.5B.
-
Who are Coloplast’s competitors?
Smith & Nephew, Avanos Medical, Aspen Surgical Products, Kimal, and Medtronic are some of the 22 competitors of Coloplast.
-
What is Coloplast’s annual earnings per share (EPS)?
Coloplast’s EPS for 12 months was $2.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process